Symphogen Launches New Website and Marketing Materials
News Dec 21, 2005
Symphogen has recently launched a new website accompanied by several new factsheets detailing the company, technology and products.
Symphogen’s recombinant polyclonal antibody products are geared to the treatment of diseases caused by complex target antigens such as cancer, infectious diseases, transplantation rejection, and allergy.
The Company’s lead product, which combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN), is expected to enter the clinic in 2006.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.